Green Tea Lozenges for the Management of Dry Mouth

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01647737
Recruitment Status : Completed
First Posted : July 24, 2012
Results First Posted : March 18, 2015
Last Update Posted : March 18, 2015
Information provided by (Responsible Party):
Scott DeRossi, Augusta University

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Conditions: Xerostomia
Sjogren Syndrome
Dry Mouth
Interventions: Dietary Supplement: MighTeaFlow
Dietary Supplement: Xylitol

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Potential candidates were identified from a pool of previously diagnosed subjects and new subjects referred to the Clinical Center for Oral Medicine, School of Dentistry, Georgia Regents University

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Subjects had a diagnosis of Xerostomia

Reporting Groups
Green Tea Lozenge


Green tea lozenge: 4-6 times daily

Placebo Xylitol lozenge 4 - 6 times daily

Participant Flow:   Overall Study
    Green Tea Lozenge   Placebo
STARTED   30   30 
COMPLETED   26   25 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Consented subjects diagnosed with Xerostomia and meeting all inclusion exclusion criteria

Reporting Groups
Green Tea Lozenge


Green tea lozenge: 4-6 times daily



Green tea lozenge: 4-6 times daily

Total Total of all reporting groups

Baseline Measures
   Green Tea Lozenge   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 30   30   60 
[Units: Participants]
<=18 years   0   0   0 
Between 18 and 65 years   17   16   33 
>=65 years   13   14   27 
[Units: Participants]
Female   30   29   59 
Male   0   1   1 
Region of Enrollment 
[Units: Participants]
United States   30   30   60 

  Outcome Measures

1.  Primary:   Change in Salivary Flow From Baseline   [ Time Frame: 8 weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Dr. Scot DeRossi, Chairman of the ORal Medicine & Diagnostic Sciences Department
Organization: Georgia Regents University
phone: 706-721-2607

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Scott DeRossi, Augusta University Identifier: NCT01647737     History of Changes
Other Study ID Numbers: GHSU Lozenge Xerostomia Study
First Submitted: May 14, 2012
First Posted: July 24, 2012
Results First Submitted: January 23, 2015
Results First Posted: March 18, 2015
Last Update Posted: March 18, 2015